AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FTAI Aviation Ltd

Eli Lilly

MercadoLibre

SPS Commerce

Wall Street has rewarded certain growth stocks handsomely this year. I believe now may be an opportune time to buy some of these high-flyers, even after the recent tech selloff.

7 Explosive Growth Stocks Set to Soar in 2024

AstraZeneca PLC (NASDAQ:AZN ) Q2 2024 Earnings Conference Call July 25, 2024 6:45 AM ET Company Participants Andy Barnett - Head, IR Pascal Soriot - Executive Director & CEO Aradhana Sarin - Executive Director & CFO David Fredrickson - EVP, Oncology Business Susan Galbraith - EVP, Oncology Research and Development Ruud Dobber - EVP & President, BioPharmaceuticals Sharon Barr - EVP, BioPharmaceuticals Research and Development Marc Dunoyer - CEO, Alexion and Chief Strategy Officer, AstraZeneca Dave Fredrickson - EVP, Oncology Business Leon Wang - EVP, International and President, China Conference Call Participants Mark Purcell - Morgan Stanley James Gordon - JPMorgan Gonzalo Artiach - Danske Bank Rajan Sharma - Goldman Sachs Sachin Jain - Bank of America Merrill Lynch Tim Anderson - Wolfe Emmanuel Papadakis - Deutsche Bank Peter Welford - Jefferies Seamus Fernandez - Analyst Matthew Weston - UBS Mattias Haggblom - Handelsbanken Pete Verdult - Citi Luisa Hector - Berenberg Capital Markets Operator Welcome to AstraZeneca's Half Year and Q2 Results 2024 Webinar for Investors and Analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.

AstraZeneca PLC (AZN) Q2 2024 Earnings Call Transcript

The chief executive of AstraZeneca has criticised a public health body for refusing to make one of its breast cancer treatments available to NHS patients in England and Wales.

Govt body's procedures means people with cancer aren't getting drug - AstraZeneca boss

AstraZeneca topped Wall Street revenue and earnings estimates. The big pharma company also raised its full-year revenue and earnings guidance.

Why AstraZeneca Stock Is Sliding Today

The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Astrazeneca (AZN) Reports Q2 Earnings: What Key Metrics Have to Say

AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.

AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View

AstraZeneca stock slipped Thursday despite beating quarterly expectations and raising its earnings outlook for the year.

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook

AstraZeneca (AZN) posted better-than-expected results for the second quarter and lifted its full-year guidance Thursday as revenue grew in nearly all of its product categories compared to the same time last year.

AstraZeneca Posts Earnings Beat, Lifts Guidance on Strong Sales

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--H1/Q2 2024 Earnings Release (25 July 2024).

AstraZeneca's H1 and Q2 2024 Financial Results

AstraZeneca PLC (LSE:AZN) has raised its guidance for revenue and earnings this year after first-half sales jumped by 18%. Pascal Soriot, chief executive, said:  "Building on our strong growth in the first half of the year and continued underlying demand for our medicines we are upgrading our FY 2024 guidance for both Total Revenue and Core EPS.

AstraZeneca ups annual guidance as first half half revenues surge

Anglo-Swedish drugmaker AstraZeneca on Thursday raised its sales and profit forecast for 2024 and topped analyst expectations for second-quarter revenue, buoyed by demand for its therapies for cancer and rare diseases.

AstraZeneca lifts full-year outlook on upbeat demand for therapies

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?

AstraZeneca PLC (LSE:AZN) releases its quarterly results next Thursday in the wake of an Investor Day at which outlined its bold plan to almost double its turnover to $80 billion by the end of the decade bolstered by a strong pipeline of new drugs, particularly in oncology. Against this backdrop, and a strong financial performance in the first quarter, analysts are now asking whether the Anglo-Swedish drugs giant will upgrade its already bullish financial forecasts for 2024.

AstraZeneca could upgrade expectations after setting out bold growth plans

AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several candidates having blockbuster potential.

AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?

Diageo

Unilever

Keir Stamer's style is the polar opposite of Donald Trump. Many wondered if he was too boring to be U.K. Prime Minister.

These Stocks Offer Gains Without the U.S. Political Drama

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

In the closing of the recent trading day, Astrazeneca (AZN) stood at $79.76, denoting a +1.49% change from the preceding trading day.

Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Astrazeneca (AZN) is a Strong Growth Stock

LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced that its previously announced acquisition by the global pharmaceutical company, AstraZeneca, has closed.

AstraZeneca Closes Acquisition of Amolyt Pharma

British pharmaceuticals megacap AstraZeneca PLC (LSE:AZN) shares surged nearly a percentage point higher on Friday, reflecting what broker Shroe Capital Markets sees as a “catalyst-rich period ahead”. “AstraZeneca outlined its ‘bold ambition' to deliver $80bn revenue by 2030 during its recent Investor Day, something we believe looks readily deliverable given the depth, breadth and momentum of the R&D pipeline, particularly in oncology,” said Shore Cap.

AstraZeneca has a 'catalyst-rich' period ahead

Abbott Labs

Intuitive Surgical

Merck

PACS Group, Inc.

Pfizer

Tenet Healthcare

In my view, it's important for every individual to invest in equities. By just holding cash in a back account, there is bound to be loss of purchasing power when adjusted for inflation.

7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns

The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on data from the phase III FLAURA2 study.

AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC

BAE Systems PLC

British American Tobacco

National Grid

Polar Power

RELX

Smith & Nephew

Unfortunately, UK investors have had to suffer weak or negative capital gains in recent years to get those high yields. The good news is that the UK remains an attractive market for dividend investors. Don't forget that companies usually retain some of their earnings to fund expansion and growth, so dividends have (on average) grown ahead of inflation over the medium and long term,.

U.K. Top 40 Quality Dividend Stocks: Summer 2024

Shares of Aptamer Group PLC (AIM:APTA) were up 12% after announcing a new collaboration with AstraZeneca PLC (LSE:AZN) to explore the use of Optimer technology for targeted delivery of siRNA, a type of genetic material used in therapies. Optimers are synthetic molecules designed to bind specifically to target cells, enhancing the delivery and effectiveness of treatments.

News for AstraZeneca Stock (AZN)